Drug Trial Radar · NCT07834398
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Nov 14, 2025
Primary completion
Apr 13, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Zagazig UniversityGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Najran University
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.
Conditions
- Non-diabetec Obesity
- Obesity (Disorder)
Interventions
DulaglutideDrug
weight control drug dulaglutide 1.5 mg subcutaneous injection GLP-1 receptor agonist
SemagludtideDrug
Weight control drug semaglutide 2.4 mg subcutanous injection GLP-1 receptor agonist
TirzepatideDrug
Weight control drug tirzepatide 15 mg subcutanous injection GLP-1 receptor agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in body weight at 3 and 6 monthsTime frame: Baseline, Week 12 (3 months) and Week 24 (6 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Najran General Hospital
Najran, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.